Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy and Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have a Confirmed Genetic BRCA 1 and/or BRCA2 Mutation

NCT01078662 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01078662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01078662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy and Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have a Confirmed Genetic BRCA 1 and/or BRCA2 Mutation
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
February 21, 2010
Completion date
August 12, 2024
Enrollment
298 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced tumours, breast, ovarian, pancreatic, prostate